Diagnosis of Endocrine Dysfunctions in Covid-19

Overview

As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course. Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described. Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease. In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.

Full Title of Study: “Diagnosis of Endocrine Dysfunctions in Covid-19 : Explorations of the Plasma Renin and Aldosterone Levels in Patients With Covid-19 Infection.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 1, 2020

Clinical Trial Outcome Measures

Primary Measures

  • Plasma aldosterone levels
    • Time Frame: 1 day (at inclusion)
    • Plasma aldosterone levels
  • Plasma renin levels
    • Time Frame: 1 day (at inclusion)
    • Plasma renin levels

Secondary Measures

  • covid-19 infection severity
    • Time Frame: 1 day (at inclusion)
    • covid-19 infection severity : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
  • Maximum severity of Covid-19 infection
    • Time Frame: 1 day (at inclusion)
    • Maximum severity of Covid-19 infection using a seven-category ordinal scale at at the end of hospitalization : Ordinal scale of 7 values from 1 to 7 (1- not hospitalized, no limitation on activities; 2- not hospitalized, limitations on activities; 3- hospitalized, not requiring supplemental oxygen; 4- hospitalized, requiring supplemental oxygen; 5- hospitalized, on non-invasive ventilation or high flow oxygen devices; 6- hospitalized, on invasive mechanical ventilation or ECMO and 7- death).
  • Plasma aldosterone level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma aldosterone level
  • Plasma ACTH level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma ACTH level
  • Plasma cortisol level
    • Time Frame: 1 day (at inclusion)
    • Plasma cortisol level
  • Plasma cortisol level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma cortisol level
  • Plasma T3l level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma T3l level
  • Plasma T3l level
    • Time Frame: 1 day (at inclusion)
    • Plasma T3l level
  • Plasma ACTH level
    • Time Frame: 1 day (at inclusion)
    • Plasma ACTH level
  • Plasma LH level
    • Time Frame: 1 day (at inclusion)
    • Plasma LH level
  • Plasma LH level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma LH level
  • Plasma DHEA level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma DHEA level
  • Plasma DHEA level
    • Time Frame: 1 day (at inclusion)
    • Plasma DHEA level
  • Plasma estradiol (female) or testosterone (male) level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma estradiol (female) or testosterone (male) level
  • Plasma estradiol (female) or testosterone (male) level
    • Time Frame: 1 day (at inclusion)
    • Plasma estradiol (female) or testosterone (male) level
  • Plasma FSH level
    • Time Frame: 1 day (at the end of hospitalization)
    • Plasma FSH level
  • Plasma FSH level
    • Time Frame: 1 day (at inclusion)
    • Plasma FSH level
  • type of treatments
    • Time Frame: 1 day
    • type of treatments
  • Clinical characteristics
    • Time Frame: 1 day
    • Clinical characteristics extracted from electronic medical
  • radiological characteristics
    • Time Frame: 1 day
    • radiological characteristics : quantification of the percentage of lesional damage to the pulmonary parenchyma

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with Covid-19 diagnosis and hospitalized in our clinic Exclusion criteria:
  • Minor patient
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University Hospital, Montpellier
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Philippe GUILPAIN, MD, PhD, Study Director, University Hospital, Montpellier

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.